Abstract
Introduction: Tobacco contains several genotoxic agents including N-nitrosamine which has the potential to cause significant nuclear damage. Nuclear blebbing is a form of protrusion on the nuclear membrane and could potentially be caused by tobacco-induced genotoxicity and is closely associated with malignancy. Thus, the present study aimed to assess if tobacco-associated oral potentially malignant disorders including oral submucous fibrosis (OSF) and oral leukoplakia have a higher nuclear blebbing frequency than patients with normal oral mucosa with no history of tobacco use. Methods: The sample consisted of patients with OSF (n = 30) and oral leukoplakia (n = 10) and normal oral mucosa (n = 10). Exfoliated cells collected from the study groups were smeared on a clean microscopic slide and stained by May-Grunwald-Giemsa stain. A baseline frequency of nuclear blebbing was evaluated using a bright-field microscope with a ×100 objective. The number of nuclear blebbing per 1,000 epithelial cells was recorded and expressed in percentage. ANOVA, the Mann-Whitney U test, and Spearman’s correlation were used to analyze the data. Results: The mean rank of distribution of nuclear blebbing showed significant difference between all 3 groups, with the highest frequency noted in leukoplakia, followed by oral submucous and normal oral mucosa. Within OSF, the frequency of nuclear blebbing significantly increased from early stage to advanced stage. In OSF, a statistically significant positive linear correlation was noted between duration (in years), frequency (per day) of tobacco use, clinical grading, and nuclear blebbing. Discussion/Conclusions: The frequency of nuclear blebbing was significantly higher in oral potentially malignant disorders than normal mucosa. Nuclear blebbing also exhibited a strong dose- and time-dependent correlation with tobacco usage and clinical staging in OSF. The nuclear blebbing frequency could be a noninvasive, economic tool to assess malignant risk in tobacco-induced oral potentially malignant disorders.
References
1.
Fenech
M
, Kirsch-Volders
M
, Natarajan
AT
, Surralles
J
, Crott
JW
, Parry
J
, Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells
. Mutagenesis
. 2011 Jan
;26
(1
):125
–32
. .2.
Driscoll
MK
, Albanese
JL
, Xiong
ZM
, Mailman
M
, Losert
W
, Cao
K
. Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell?
Aging
. 2012 Feb
;4
(2
):119
–32
. .3.
Goldman
RD
, Shumaker
DK
, Erdos
MR
, Eriksson
M
, Goldman
AE
, Gordon
LB
, Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome
. Proc Natl Acad Sci U S A
. 2004 Jun
;101
(24
):8963
–8
. .4.
Gisselsson
D
, Björk
J
, Höglund
M
, Mertens
F
, Dal Cin
P
, Åkerman
M
, Abnormal nuclear shape in solid tumors reflects mitotic instability
. Am J Pathol
. 2001 Jan
;158
(1
):199
–206
. .5.
Maraldi
NM
, Lattanzi
G
, Capanni
C
, Columbaro
M
, Merlini
L
, Mattioli
E
, Nuclear envelope proteins and chromatin arrangement: a pathogenic mechanism for laminopathies
. Eur J Histochem
. 2006
;50
(1
):1
–8
.6.
Capell
BC
, Collins
FS
. Human laminopathies: nuclei gone genetically awry
. Nat Rev Genet
. 2006 Dec
;7
(12
):940
–52
. .7.
Zink
D
, Fischer
AH
, Nickerson
JA
. Nuclear structure in cancer cells
. Nat Rev Cancer
. 2004 Sep
;4
(9
):677
–87
. .8.
Mounkes
L
, Kozlov
S
, Burke
B
, Stewart
CL
. The laminopathies: nuclear structure meets disease
. Curr Opin Genet Dev
. 2003 Jun
;13
(3
):223
–30
. .9.
Rodriguez
R
, Rubio
R
, Masip
M
, Catalina
P
, Nieto
A
, de la Cueva
T
, Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells
. Neoplasia
. 2009 Apr
;11
(4
):397
–407
. .10.
Sharma
S
, Bhonde
R
. Influence of nuclear blebs and micronuclei status on the growth kinetics of human mesenchymal stem cells
. J Cell Physiol
. 2015 Mar
;230
(3
):657
–66
. .11.
Tchernev
G
, Orfanos
CE
. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings
. J Cutan Pathol
. 2007 Mar
;34
(3
):247
–56
. .12.
Philipp-Staheli
J
, Kim
KH
, Liggitt
D
, Gurley
KE
, Longton
G
, Kemp
CJ
. Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development
. Oncogene
. 2004 Jan
;23
(4
):905
–13
. .13.
Kumar
V
, Rao
NN
, Nair
NS
. Micronuclei in oral squamous cell carcinoma. A marker of genotoxic damage
. Indian J Dent Res
. 2000
;11
(3
):101
–6
.14.
Jemal
A
, Bray
F
, Center
MM
, Ferlay
J
, Ward
E
, Forman
D
. Global cancer statistics
. CA Cancer J Clin
. 2011 Mar
;61
(2
):69
–90
. .15.
Califano
J
, van der Riet
P
, Westra
W
, Nawroz
H
, Clayman
G
, Piantadosi
S
, Genetic progression model for head and neck cancer: implications for field cancerization
. Cancer Res
. 1996 Jun
;56
(11
):2488
–92
.16.
Fenech
M
. The in vitro micronucleus technique
. Mutat Res Mol Mech Mutagen
. 2000 Nov
;455
(1–2
):81
–95
. .17.
Hanahan
D
, Weinberg
RA
. Hallmarks of cancer: the next generation
. Cell
. 2011 Mar
;144
(5
):646
–74
. .18.
Negrini
S
, Gorgoulis
VG
, Halazonetis
TD
. Genomic instability: an evolving hallmark of cancer
. Nat Rev Mol Cell Biol
. 2010 Mar
;11
(3
):220
–8
. .19.
Vargas
JD
, Hatch
EM
, Anderson
DJ
, Hetzer
MW
. Transient nuclear envelope rupturing during interphase in human cancer cells
. Nucleus
. 2012 Jan
;3
(1
):88
–100
. .20.
Denais
CM
, Gilbert
RM
, Isermann
P
, McGregor
AL
, te Lindert
M
, Weigelin
B
, Nuclear envelope rupture and repair during cancer cell migration
. Science
. 2016 Apr
;352
(6283
):353
–8
. .21.
Broers
JLV
, Peeters
EAG
, Kuijpers
HJH
, Endert
J
, Bouten
CVC
, Oomens
CWJ
, Decreased mechanical stiffness in LMNA−/− cells is caused by defective nucleo-cytoskeletal integrity: implications for the development of laminopathies
. Hum Mol Genet
. 2004 Nov
;13
(21
):2567
–80
.22.
Bercht Pfleghaar
K
, Taimen
P
, Butin-Israeli
V
, Shimi
T
, Langer-Freitag
S
, Markaki
Y
, Gene-rich chromosomal regions are preferentially localized in the lamin B deficient nuclear blebs of atypical progeria cells
. Nucleus
. 2015 Jan
;6
(1
):66
–76
. .23.
Raab
M
, Gentili
M
, de Belly
H
, Thiam
HR
, Vargas
P
, Jimenez
AJ
, ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA damage and cell death
. Science
. 2016 Apr
;352
(6283
):359
–62
. .24.
Toledo
F
, Le Roscouet
D
, Buttin
G
, Debatisse
M
. Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at early steps of mammalian gene amplification
. EMBO J
. 1992 Jul
;11
(7
):2665
–73
. .25.
Kazanowska
K
, Hałoń
A
, Radwan-Oczko
M
. The role and application of exfoliative cytology in the diagnosis of oral mucosa pathology: contemporary knowledge with review of the literature
. Adv Clin Exp Med
. 2014 Mar–Apr
;23
(2
):299
–305
. .26.
Shimizu
N
. Molecular mechanisms of the origin of micronuclei from extrachromosomal elements
. Mutagenesis
. 2011 Jan
;26
(1
):119
–23
. .27.
Canniff
JP
, Harvey
W
, Harris
M
. Oral submucous fibrosis: its pathogenesis and management
. Br Dent J
. 1986 Jun
;160
(12
):429
–34
. .28.
Neville
BW
, Day
TA
. Oral cancer and precancerous lesions
. CA Cancer J Clin
. 2002 Jul
;52
(4
):195
–215
. .29.
van der Waal
I
. Historical perspective and nomenclature of potentially malignant or potentially premalignant oral epithelial lesions with emphasis on leukoplakia-some suggestions for modifications
. Oral Surg Oral Med Oral Pathol Oral Radiol
. 2018 Jun
;125
(6
):577
–81
. .30.
Bewley
AF
, Farwell
DG
. Oral leukoplakia and oral cavity squamous cell carcinoma
. Clin Dermatol
. 2017 Sep
;35
(5
):461
–7
. .31.
Warnakulasuriya
S
, Ariyawardana
A
. Malignant transformation of oral leukoplakia: a systematic review of observational studies
. J Oral Pathol Med
. 2016 Mar
;45
(3
):155
–66
. .32.
Proia
NK
, Paszkiewicz
GM
, Nasca
MA
, Franke
GE
, Pauly
JL
. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer: a review
. Cancer Epidemiol Biomarkers Prev
. 2006 Jun
;15
(6
):1061
–77
. .33.
Caruso
RA
, Fedele
F
, Crisafulli
C
, Paparo
D
, Parisi
A
, Lucianò
R
, Abnormal nuclear structures (micronuclei, nuclear blebs, strings, and pockets) in a case of anaplastic giant cell carcinoma of the thyroid: an immunohistochemical and Ultrastructural Study
. Ultrastruct Pathol
. 2011 Feb
;35
(1
):14
–8
. .34.
Ambros
IM
, Rumpler
S
, Luegmayr
A
, Hattinger
CM
, Strehl
S
, Kovar
H
, Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation: sign of tumour cell revertance?
Eur J Cancer
. 1997 Oct
;33
(12
):2043
–9
. .35.
Iwasaki
H
, Ohjimi
Y
, Ishiguro
M
, Isayama
T
, Fujita
C
, Kaneko
Y
, Supernumerary ring chromosomes and nuclear blebs in some low-grade malignant soft tissue tumours: atypical lipomatous tumours and dermatofibrosarcoma protuberans
. Virchows Arch
. 1998 Jun
;432
(6
):521
–8
. .36.
Urciuoli
E
, Petrini
S
, D’Oria
V
, Leopizzi
M
, Rocca
CD
, Peruzzi
B
. Nuclear lamins and emerin are differentially expressed in osteosarcoma cells and scale with tumor aggressiveness
. Cancers
. 2020 Feb
;12
(2
):443
. .37.
Srivastava
N
, Nader
GPF
, Williart
A
, Rollin
R
, Cuvelier
D
, Lomakin
A
, Nuclear fragility, blaming the blebs
. Curr Opin Cell Biol
. 2021 Jun
;70
:100
–8
. .38.
Liu
PZ
, Stephens
AD
, Banigan
EJ
, Almassalha
L
, Backman
V
, Adams
SA
, Nuclear blebbing solely as a function of chromatin compaction state
. Biochem Mol Biol
. 2018
. .39.
Reis-Sobreiro
M
, Chen
JF
, Novitskaya
T
, You
S
, Morley
S
, Steadman
K
, Emerin deregulation links nuclear shape instability to metastatic potential
. Cancer Res
. 2018 Nov
;78
(21
):6086
–97
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
